Judge Faith Hochberg, District of New Jersey, denied Pfizer’s motion to dismiss claims alleging that it unlawfully sought to monopolize the market for gabapentin products. Pharmacies purchasing the drugs argued that Pfizer violated the antitrust laws by, inter alia, manipulating the patent approval process and filing sham law suits. The court rejected Pfizer’s defenses that its actions were privileged or that certain claims were barred by the statute of limitations.